

Oncology Today with Dr Neil Love: Interstitial Lung Disease in Patients Receiving Anticancer Therapy

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was observed regarding the incidence of drug-related interstitial lung disease (ILD) in 510 patients with breast cancer who received trastuzumab deruxtecan (T-DXd) in 5 single-arm trials?**
 - ILD occurred in 8% of patients and the majority was Grade 1, 2 and 5
 - ILD occurred in 13% of patients and the majority was Grade 2 and 3
 - ILD occurred in 21% of patients and the majority was Grade 1 and 2
- 2. For which grades of ILD should an anticancer therapy be permanently discontinued?**
 - Any grade
 - Grades 2, 3 or 4
 - Grades 3 or 4 only
- 3. Which of the following best describes the time to onset of ILD among patients receiving T-DXd?**
 - Most events occurred within the first month of treatment
 - Most events occurred within the first 12 months of treatment
 - Most events occurred between 15 and 18 months of treatment
- 4. Which of the following anticancer drugs is frequently associated with the development of transient asymptomatic pulmonary opacities?**
 - Gefitinib
 - Trastuzumab deruxtecan
 - Osimertinib
 - Patritumab deruxtecan
- 5. Which of the following factors was NOT associated with a potential risk for the development of ILD in a recent meta-analysis of 1,150 patients treated with T-DXd across 9 single-arm trials?**
 - Higher dose of T-DXd
 - Age ≥ 65 years
 - Time since diagnosis ≥ 4 years
 - Moderate/severe renal impairment